Table 2.
Zone | Stage | Plus Disease | Category | ||||||
---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||
Examination | No. | RSD Agreement, % (95%CI) |
Weighted κ | RSD Agreement, % (95%CI) |
Weighted κ | RSD Agreement, % (95%CI) |
Weighted κ | RSD Agreement, % (95%CI) |
Weighted κ |
Telemedicine | |||||||||
| |||||||||
Grader 1 | 1553 | 88 (87–90) | 0.56 | 70 (68–73) | 0.70 | 93 (92–94) | 0.82 | 72 (70–74) | 0.68 |
| |||||||||
Grader 2 | 1553 | 87 (85–88) | 0.48 | 71 (69–73) | 0.69 | 87 (85–89) | 0.68 | 73 (71–76) | 0.70 |
| |||||||||
Grader 3 | 1553 | 89 (88–91) | 0.60 | 85 (84–87) | 0.85 | 97 (96–98) | 0.91 | 86 (85–88) | 0.85 |
| |||||||||
P valuea | NA | .06 | NA | <.001 | NA | <.001 | NA | <.001 | NA |
| |||||||||
Ophthalmoscopy | |||||||||
| |||||||||
Clinician 1 | 616 | 95 (93–97) | 0.83 | 94 (92–96) | 0.91 | 95 (94–97) | 0.86 | 94 (92–96) | 0.91 |
| |||||||||
Clinician 2 | 162 | 96 (93–99) | 0.91 | 88 (83–94) | 0.86 | 78 (71–84) | 0.57 | 81 (75–87) | 0.75 |
| |||||||||
Clinician 3 | 82 | 94 (89–99) | 0.89 | 77 (68–86) | 0.69 | 72 (62–82) | 0.13 | 77 (68–86) | 0.68 |
| |||||||||
Clinician 4 | 172 | 97 (95–99) | 0.83 | 89 (85–94) | 0.76 | 97 (95–99) | 0.70 | 92 (88–96) | 0.82 |
| |||||||||
Clinician 5 | 446 | 86 (83–90) | 0.63 | 82 (78–86) | 0.70 | 82 (78–85) | 0.17 | 71 (66–75) | 0.51 |
| |||||||||
P valuea | NA | <.001 | NA | <.001 | NA | <.001 | NA | <.001 | NA |
Abbreviations: NA, not applicable; ROP, retinopathy of prematurity; RSD, reference standard diagnosis.
Based on Pearson χ2 test.